(Q37125935)

18 August 2017

1 reference

title

Drug insight: antiangiogenic therapies for gastrointestinal cancers--focus on monoclonal antibodies (English)

1 reference

18 August 2017

1 reference

angiogenesis inhibitor

1 reference

1 reference

3

Wolff Schmiegel

1 reference

18 August 2017

Anke Reinacher-Schick

series ordinal

1

object named as

Anke Reinacher-Schick

1 reference

18 August 2017

Michael Pohl

2

1 reference

18 August 2017

language of work or name

English

0 references

publication date

1 April 2008

1 reference

Nature Reviews Gastroenterology & Hepatology

18 August 2017

published in

1 reference

18 August 2017

volume

5

1 reference

18 August 2017

issue

5

1 reference

18 August 2017

page(s)

250-267

1 reference

Tumor angiogenesis: therapeutic implications

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

Transplacental carcinogenesis by stilbestrol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

The biology of VEGF and its receptors

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

Determination of molecular marker expression can predict clinical outcome in colon carcinomas.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

Prognostic value of vascular endothelial growth factor expression in gastric carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

High expression of vascular endothelial growth factor predicts early recurrence and poor prognosis after curative resection for ductal adenocarcinoma of the pancreas.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

pRb2/p130, vascular endothelial growth factor, p27(KIP1), and proliferating cell nuclear antigen expression in hepatocellular carcinoma: their clinical significance

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

Induction of neuropilin-1 and vascular endothelial growth factor by epidermal growth factor in human gastric cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

Vascular endothelial growth factor is a secreted angiogenic mitogen

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

Angiogenesis stimulated by PDGF-CC, a novel member in the PDGF family, involves activation of PDGFR-alphaalpha and -alphabeta receptors

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

Vascular endothelial growth factor/vascular permeability factor is an autocrine growth factor for AIDS-Kaposi sarcoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

Angiogenesis in cancer and other diseases

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

Analysis of PDZ domain-ligand interactions using carboxyl-terminal phage display

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

The Vascular Endothelial Growth Factor Receptor Flt-1 Mediates Biological Activities

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

VEGF receptor signalling - in control of vascular function

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

Vascular integrins in tumor angiogenesis: mediators and therapeutic targets

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

Mechanisms and future directions for angiogenesis-based cancer therapies

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

Integrins and angiogenesis: a sticky business

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

Promoting angiogenesis to a fault

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

Up-regulation of delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

The Delta paradox: DLL4 blockade leads to more tumour vessels but less tumour growth

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

From gut homeostasis to cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

Delta4, an endothelial specific notch ligand expressed at sites of physiological and tumor angiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

A monoclonal antibody that blocks VEGF binding to VEGFR2 (KDR/Flk-1) inhibits vascular expression of Flk-1 and tumor growth in an orthotopic human breast cancer model

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

Anti-VEGF-A therapy reduces lymphatic vessel density and expression of VEGFR-3 in an orthotopic breast tumor model

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

Selective blockade of vascular endothelial growth factor receptor 2 with an antibody against tumor-derived vascular endothelial growth factor controls the growth of human pancreatic adenocarcinoma xenografts

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

VEGF-Trap: a VEGF blocker with potent antitumor effects

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

Regression of established tumors and metastases by potent vascular endothelial growth factor blockade

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

Lessons from phase III clinical trials on anti-VEGF therapy for cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

Human endothelial cells synthesize and express an Arg-Gly-Asp-directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

Volociximab, a chimeric integrin alpha5beta1 antibody, inhibits the growth of VX2 tumors in rabbits

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumours

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

Combination of a monoclonal anti-phosphatidylserine antibody with gemcitabine strongly inhibits the growth and metastasis of orthotopic pancreatic tumors in mice

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

Incidence and patterns of recurrence following curative resection for colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

Rapid vascular regrowth in tumors after reversal of VEGF inhibition

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

Response evaluation and long-term follow-up

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

Liver regeneration is an angiogenesis- associated phenomenon

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

Lack of Evidence for Increased Operative Morbidity After Hepatectomy with Perioperative Use of Bevacizumab: A Matched Case-Control Study

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

New therapies for hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

Systemic chemotherapy of liver tumors

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

Angiogenesis in brain tumours

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1097

7 January 2021

Identifiers

DOI

10.1038/NCPGASTHEP1097

1 reference

18 August 2017

1 reference